Next Generation Pyrosequencing(R) System; PyroMark(TM)Q24 Pyrosequencing
Technology in a 24 Well Format for Low Throughput Epigenetic Studies
UPPSALA, Sweden, March 31 /PRNewswire/ -- Pyrosequencing AB, a subsidiary of Biotage AB today announced the launch of PyroMark(TM)Q24 the latest in the range of Pyrosequencing(R) Systems. This new high-performance platform includes a complete software package for the study of genetic and epigenetic variation of genes, providing CpG methylation allele quantification and mutation analysis. These studies are used for a wide range of clinical research, for example the identification and tracking of changes involved in various forms of cancer. Studying these changes using Pyrosequencing(R) technology, which is based on the principals of sequencing by synthesis, is an ideal choice for genetic analysis in clinical research. The output information is based on real sequence data providing integrated quality control and security in the quality of the results.
The system, aimed at lower throughput needs, optimizes the management of fewer samples. The 24 well plate format and the ability to run and analyze both mutation and methylation assays on the same plate provides an ideal solution for managing low sample numbers or mixed analysis needs while providing the accuracy, flexibility and convenience offered by Pyrosequencing(R) technology.
Until now Pyrosequencing(R) technology has only been available in higher throughput systems, placing it out of the reach of many researchers. "With the introduction of the new PyroMark(TM)Q24 system we plan to open up the availability of Pyrosequencing(R) technology to many more researchers." Said Torben Jorgensen President and CEO of Biotage AB.
The PyroMark(TM)Q24 performance has been successfully demonstrated at
sites in the US and Europe. Pyromark(TM)Q24 was shown to provide
reproducible and reliable results at the Dept of Pathology, Uppsala
|SOURCE Biotage AB|
Copyright©2008 PR Newswire.
All rights reserved